OncoMatch/Clinical Trials/NCT02633514

Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma

Is NCT02633514 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Cisplatin and Etoposide for thymoma and thymic carcinoma.

Phase 3RecruitingFudan UniversityNCT02633514Data as of May 2026

Treatment: Cisplatin · Etoposide — This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

Check if I qualify

Extracted eligibility criteria

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: radiotherapy

Patients underwent radiotherapy

Cannot have received: chemotherapy

Patients underwent chemotherapy

Lab requirements

Blood counts

adequate bone marrow function

Kidney function

adequate renal function

Liver function

adequate hepatic function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify